MedTrace Logo

Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

NCT00497666 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2007-07-09

No results posted yet for this study

Summary

Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.

We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.

Conditions

  • Diabetes
  • Diabetic Nephropathy
  • Renal Protection

Interventions

DRUG

Rosiglitasone (retrospective observation)

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Leonid S Feldman · Nephrology Division, Assaf Harofeh Medical Center, Zerifin,

  • Leonid S Feldman · Assaf-Harofeh Medical Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2007-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497666 on ClinicalTrials.gov